Navigation Links
Identification of differential proteins in maternal serum with Down syndrome
Date:6/7/2012

Prenatal screening for Down syndrome (DS) is still in need of improvement. Perinatal medicine experts have worked hard to find new biomarkers for screening of DS. Dr. Shi he Shao and his co-investigators, from Jiangsu University and Changzhou Woman and Children Health Hospital, report in the May 2012 issue of Experimental Biology and Medicine that they have successfully identified twenty-nine differentially expressed proteins in maternal serum from pregnancies carrying DS fetuses with proteomic approaches. These differential proteins offer the possibility of improving the performance of DS screening in the future. The functional roles of these proteins also possibly have a relationship with the development of DS.

Dr. Shao said "To date, a very limited number of studies have been carried out to analyze maternal blood in search for biomarkers of DS." "We have successfully identified the greatest number of potential DS biomarker proteins in maternal serum."

Dr. Yu said "We used the proteomic approaches of two dimensional gel electrophoresis (2-DE) and MALDI mass spectrometry and they proved to be of benefit in identifying potential serum biomarkers to detect DS."

Dr. Qiu wei Wang said "Among 29 proteins, two proteins ceruloplasmin and complement factor B (CP and CFB) were the most notable. Both were significantly increased in DS maternal serum and their functional roles suggest a relationship with the development of DS."

These differential proteins offers the possibility of further improving the performance of DS screening but Dr. Shao concludes that "it still needs clinical verification as a prenatal screen and we will conduct corollary studies to understand how these candidate proteins are related to the etiology and function of DS."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Prenatal screening for Down Syndrome has a rate of detection which is at best 75 to 85% with a 5% false positive rate and a lower rate of detection found in developing countries. The proteomic approach of Shao and colleagues offers new biomarkers which could lead to higher rates of detection and lower false positive rates. Further clinical testing of this approach is warranted based on this study."


'/>"/>

Contact: Shi-he Shao
shaoshihe2006@163.com
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. SRI Sarnoffs Iris on the Move® N-Glance™ Identification System Receives Lenel Factory Certification
2. APS issues new policy requiring identification of sex or gender in reporting scientific research
3. Speeding up drug discovery with rapid 3-D mapping of proteins
4. A non-invasive intracellular thermometer with fluorescent proteins has been created
5. Discovered a new checkpoint of cell cycle control through joint action of 2 proteins
6. UCLA researchers develop way to strengthen proteins with polymers
7. Discovery of plant proteins may boost agricultural yields and biofuel production
8. Discovery of a new family of key mitochondrial proteins for the function and viability of the brain
9. Gold nanoantennas detect proteins
10. More effective method of imaging proteins
11. Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology: